TL;DR
The first peptide drug. A hundred years old. Still kills bodybuilders who use it without a prescription.
What is it? A 51-amino-acid pancreatic hormone — A-chain 21 + B-chain 30 — discovered by Banting and Best in 1921. FDA-approved in 1923 from animal pancreas, made recombinantly since 1982.
What does it do? Binds the insulin receptor: GLUT4 glucose uptake, glycogen synthesis, lipogenesis, protein synthesis. Suppresses glucagon and hepatic glucose output. The master anabolic switch.
Does the evidence hold up? Among the most-studied drugs in medical history. DCCT 1993 in T1D, UKPDS 1998 in T2D, ORIGIN 2012 (glargine cardiovascular safety), DEVOTE 2017 (degludec vs glargine).
Who uses it? 8 million insulin-dependent patients in the US, 100+ million globally. Misused by bodybuilders for anabolic effects — a practice with regular fatal hypoglycemia.
Bottom line? Essential medicine for diabetics. Not a longevity peptide. Listed for reference, not for use.
What It Is
Insulin is a 51-amino-acid peptide hormone synthesized by the β-cells of the pancreatic islets of Langerhans. Its mature form consists of two polypeptide chains — an A-chain of 21 amino acids and a B-chain of 30 amino acids — held together by two interchain disulfide bonds, with a third intrachain disulfide within the A-chain. The hormone is produced as a single-chain precursor (preproinsulin → proinsulin) that is subsequently cleaved; the C-peptide fragment removed during maturation is widely used in clinical medicine as a marker of endogenous insulin production.
Insulin was first isolated and purified from canine pancreatic tissue in 1921 by Frederick Banting, Charles Best, J.J.R. Macleod, and James Collip at the University of Toronto. The 1922 treatment of 14-year-old Leonard Thompson with bovine pancreatic extract is widely regarded as the first successful pharmacologic rescue of a previously-universally-fatal disease (type 1 diabetes). Banting and Macleod received the 1923 Nobel Prize in Physiology or Medicine — one of the fastest "bench to Nobel" timelines in the history of the award. Recombinant human insulin (Humulin) was approved in 1982, the first therapeutic produced from recombinant DNA technology.
The modern insulin pharmacopeia includes multiple formulations tuned for different kinetic profiles: rapid-acting analogs (lispro [Humalog], aspart [Novolog], glulisine [Apidra], and ultra-rapid aspart [Fiasp]) with onset in 10–15 minutes and duration of 3–5 hours; short-acting regular human insulin (Humulin R, Novolin R) with onset at 30 minutes and duration of 6–8 hours; intermediate-acting NPH (neutral protamine Hagedorn) with duration of 12–18 hours; and long-acting analogs (glargine U-100 and U-300 [Lantus, Toujeo], detemir [Levemir], degludec [Tresiba]) with peakless profiles and durations of 24 hours (glargine, detemir) to 42+ hours (degludec).
Insulin is the cornerstone of type 1 diabetes management (where endogenous production is absent) and is added to advanced type 2 diabetes regimens when oral agents and GLP-1 / GIP-class therapies are insufficient. Insulin remains irreplaceable in diabetic ketoacidosis, hyperosmolar hyperglycemic state, inpatient hyperglycemia management, and perioperative glycemic control. It is also one of the most dangerous drugs in modern medicine — misuse or miscalculation produces hypoglycemia that can cause seizures, brain injury, coma, and death within minutes.
Mechanism of Action
Insulin acts via a single high-affinity receptor (the insulin receptor, IR) — a transmembrane tyrosine kinase expressed on essentially every tissue in the body. Receptor activation initiates a cascade of phosphorylation events that produce the hormone's characteristic metabolic effects.
- Insulin receptor (IR) activation — IR is a heterotetrameric α₂β₂ receptor tyrosine kinase. Insulin binding triggers autophosphorylation of the β-subunit and recruitment of insulin receptor substrate proteins (IRS-1, IRS-2), which in turn activate the PI3K / Akt and Ras / MAPK arms of the cascade. PI3K / Akt drives the metabolic effects (glucose uptake, glycogen synthesis, protein synthesis, lipogenesis); Ras / MAPK contributes to mitogenic and growth signaling.
- GLUT4 translocation (muscle + adipose) — Akt phosphorylates AS160, releasing GLUT4-containing vesicles from intracellular stores and driving their translocation to the plasma membrane. This is the proximate mechanism of insulin-stimulated glucose uptake in skeletal muscle and adipose tissue.
- Hepatic glucose output suppression — Insulin suppresses gluconeogenesis (via FOXO1 phosphorylation / nuclear exclusion) and glycogenolysis (via PP1-mediated glycogen phosphorylase inactivation). Fasting hyperglycemia in T2D primarily reflects the failure of this mechanism.
- Glycogen synthesis — Akt phosphorylates and inhibits glycogen synthase kinase 3 (GSK3), which in turn permits glycogen synthase activation. The net effect is conversion of intracellular glucose to glycogen in muscle and liver.
- Anabolic / protein synthesis (mTOR) — Akt activates mTORC1 via TSC2 inhibition, driving ribosomal protein S6 phosphorylation and 4E-BP1 inactivation — both increase cap-dependent protein translation. Insulin is additionally an antagonist of the ubiquitin-proteasome system's protein degradation pathways. The combined "promote synthesis + inhibit breakdown" action is what makes insulin the most powerful acute anabolic signal in the body.
- Lipogenesis and lipolysis suppression — Insulin stimulates ACC, FAS, and SREBP-1c expression (lipogenic program) while suppressing hormone-sensitive lipase via PDE3B activation. Net effect: fat storage, not fat release. This is the primary unwanted effect in performance use and the primary driver of visceral adiposity in chronic insulin resistance.
- α-cell glucagon suppression — Paracrine suppression of pancreatic α-cell glucagon secretion contributes to the glucose-lowering effect, particularly in the post-prandial window.
- K⁺ shift into cells — Insulin activates Na⁺/K⁺-ATPase, driving K⁺ intracellularly. Clinically exploited in hyperkalemia management (IV insulin + glucose); clinically dangerous in aggressive insulin protocols where K⁺ falls too low and cardiac arrhythmias can result.
- IGF-1 receptor cross-talk — At pharmacologic concentrations, insulin binds the closely-related IGF-1 receptor with lower affinity but measurable activity. This off-target binding is thought to underlie some of the mitogenic signaling seen with chronic supraphysiologic insulin exposure.
What the Research Shows
Insulin has one of the deepest evidence bases of any pharmaceutical — over a century of continuous clinical use, thousands of RCTs, and comprehensive pharmacovigilance. The research base is unambiguous for diabetes management; it is functionally absent for non-diabetic performance use.
- DCCT (Diabetes Control and Complications Trial, NEJM 1993, PMID 8366922) — 1,441 type 1 diabetics randomized to intensive vs conventional insulin therapy. Intensive therapy (3–4 daily injections or pump) reduced retinopathy progression by 76%, microalbuminuria by 39%, and clinical neuropathy by 60% over 6.5 years. Foundational evidence for tight glycemic control in T1D.
- UKPDS (UK Prospective Diabetes Study, Lancet 1998, PMID 9742976) — ~3,867 newly diagnosed T2D patients assigned to intensive (sulfonylurea/insulin) vs conventional therapy. Intensive therapy reduced microvascular complications by 25% at 10-year median follow-up.
- ORIGIN trial (Gerstein et al., NEJM 2012, PMID 22686416) — 12,537 dysglycemic patients at CV risk randomized to insulin glargine targeting fasting glucose ≤95 mg/dL vs standard care. Median 6.2-year follow-up. Glargine was neutral for CV outcomes; suggested tight glycemic control without macrovascular benefit in this population.
- DEVOTE trial (Marso et al., NEJM 2017, PMID 28605603) — 7,637 T2D patients with high CV risk randomized to degludec vs glargine U100. Non-inferior for MACE; degludec reduced overall and nocturnal severe hypoglycemia by ~40%.
- BEGIN / ONSET / STEP programs — Multiple pivotal trial programs for the modern basal and rapid analogs, establishing comparative hypoglycemia and HbA1c profiles for glargine U300, degludec, ultra-rapid aspart, and other agents.
- Protein synthesis / anabolism (Biolo et al., Am J Physiol 1997) — Euglycemic hyperinsulinemic clamp plus amino acid infusion in exercised humans showed insulin and AA supply synergistically drive muscle protein synthesis. Established the physiological basis for insulin's anabolic reputation.
- Insulin receptor pharmacology (Kahn, Rosen reviews) — Decades of receptor-level molecular biology establish IR signaling, GLUT4 biology, and IRS-PI3K-Akt cascade as foundational endocrine pharmacology.
- Insulin misuse case reports and forensic reviews — Multiple published case reports document fatal and near-fatal hypoglycemia from exogenous insulin in non-diabetic individuals, including bodybuilders (Elkin et al., Hum Exp Toxicol 2006; Evans & Lynch, Br J Sports Med 2003).
- Hypoglycemia lethality data — The ACCORD trial (NEJM 2008) found excess mortality in the intensive-glycemic-control arm of T2D patients, likely partially attributable to severe hypoglycemia — a cautionary signal even in closely-monitored patients.
- Performance research — No RCT evaluating insulin in healthy athletes exists. The practice is banned by the World Anti-Doping Agency (WADA Section S4, Hormone and Metabolic Modulators), and human subjects ethics boards would not approve a controlled trial given the fatality risk.
Research Limitations (Performance Use)
Insulin has an exceptional evidence base for its approved indication — diabetes management. The evidence base for performance / bodybuilding use is effectively zero controlled human trial data. All reports in this space are observational, case-series, or mechanistic extrapolation. Multiple peer-reviewed case reports describe deaths and severe morbidity from non-diabetic insulin misuse. This is one of the highest-risk practices in the optimization community and the single most common cause of "pro bodybuilder" deaths historically attributed to performance-enhancing drugs.
Human Data
Insulin has been administered to hundreds of millions of patients since 1922. The clinical dataset is vast; only the most pivotal studies are listed here.
- Banting & Best (1921–1922) — Isolation of insulin from canine pancreatic extract and first successful human treatment (Leonard Thompson, January 1922). Foundational discovery paper Banting & Best, J Lab Clin Med 1922.
- Humulin approval (1982) — First recombinant DNA-derived therapeutic approved by the FDA, introducing human-sequence insulin and ending clinical dependence on bovine and porcine pancreas extracts.
- DCCT (1993; PMID 8366922) — Established intensive insulin therapy as standard of care in T1D. Demonstrated that tight glycemic control reduces long-term microvascular complications.
- EDIC follow-up (Writing Team, JAMA 2002; PMID 12351001) — The Epidemiology of Diabetes Interventions and Complications observational follow-up of DCCT patients showed the benefits of intensive control persist for years after the randomized period (the "legacy effect" or "metabolic memory").
- UKPDS 33 + 34 (1998) — Established tight glycemic control as standard in T2D. Metformin arm (UKPDS 34) defined metformin's role as the first-line oral agent.
- Rapid analog pivotal trials (lispro: Anderson et al., Diabetes Care 1997; aspart: Lindholm et al., Diabetes Care 1999) — Established the rapid analogs' reduced post-prandial excursion and lower late-post-prandial hypoglycemia vs regular insulin.
- Glargine (HOE901) pivotal program (Rosenstock et al., Diabetes Care 2001) — Demonstrated glargine's peakless basal profile and reduced nocturnal hypoglycemia vs NPH.
- Detemir and degludec development — Further basal analog iterations with extended duration and reduced day-to-day pharmacokinetic variability.
- ORIGIN (2012) — Large CV outcome trial of insulin glargine in dysglycemic high-CV-risk patients; neutral MACE, no excess cancer signal.
- DEVOTE (2017) — Cardiovascular safety confirmation for degludec and demonstration of reduced hypoglycemia vs glargine U100.
- Inhaled insulin (Afrezza, 2014) — FDA-approved rapid-acting inhaled human insulin; niche use.
- Insulin pumps and closed-loop systems — Automated insulin delivery systems (Medtronic 670G, Tandem Control-IQ, Omnipod 5) have become standard of care in T1D, delivering continuous subcutaneous insulin infusion with CGM-driven modulation.
Dosing from the Literature
Insulin dosing in diabetes is highly individualized and supervised by endocrinology / primary care. Approximate starting points below are illustrative; actual titration requires glucose monitoring and clinician oversight.
| Indication / Context | Approximate Dose | Frequency | Notes |
|---|
| Type 1 diabetes (basal-bolus) | Total daily ~0.5–0.7 U/kg; ~50% basal, ~50% bolus split across meals | Basal once–twice daily; bolus with each meal | Individualized. Most patients on glargine / degludec basal + rapid analog with meals, or CSII pump |
| Type 2 diabetes (basal initiation) | 0.1–0.2 U/kg/day (or ~10 U) as basal | Once daily | Titrated upward by 2–4 U every 3 days based on fasting glucose |
| Type 2 diabetes (intensification) | Basal-bolus or basal + prandial when A1c remains high | Multiple daily injections | Typically after GLP-1 / oral optimization |
| Diabetic ketoacidosis (inpatient) | 0.1 U/kg/hr IV regular insulin infusion | Continuous IV | After potassium assessment; fluid / electrolyte correction protocol |
| Hyperkalemia (inpatient) | 10 U regular IV + dextrose | Single dose | K⁺ intracellular shift; ICU / ED protocol |
| Inpatient hyperglycemia (non-critical) | Basal + correction + nutritional as needed | Per protocol | ADA inpatient guidelines target 140–180 mg/dL |
Dosing Disclaimer — Performance Use
Community bodybuilding "protocols" for exogenous insulin in non-diabetic users exist but are not supported by controlled trial data, are prohibited by the World Anti-Doping Agency (Section S4), and are associated with multiple documented fatalities in the published literature. Hypoglycemia from insulin misuse can produce seizures, permanent brain injury, coma, and death within 15–30 minutes. There is no safe margin for error. This profile does not provide performance dosing. If you are considering insulin for non-medical reasons, reconsider — the risk-to-benefit ratio is among the worst in the peptide optimization space.
Reconstitution & Storage
Insulin is supplied as a ready-to-use sterile solution in vials, cartridges, and pre-filled pens. No reconstitution is required. Standard concentrations are U-100 (100 U/mL) for most formulations, with U-200, U-300 (Toujeo), and U-500 (concentrated Humulin R) available for specific clinical contexts.
| Formulation | Onset / Peak / Duration | Concentration | Storage |
|---|
| Regular (Humulin R, Novolin R) | 30 min / 2–3 h / 6–8 h | U-100 (U-500 compounded) | Refrigerate unopened. In-use 28–31 days room temp. |
| Lispro (Humalog), Aspart (Novolog), Glulisine (Apidra) | 10–15 min / 1–2 h / 3–5 h | U-100 (lispro U-200) | Refrigerate unopened. In-use 28 days room temp. |
| Ultra-rapid aspart (Fiasp) | ~5 min / 1–2 h / 3–5 h | U-100 | Same as above. |
| NPH (Humulin N, Novolin N) | 1–2 h / 4–8 h / 12–18 h | U-100 | Suspension — roll to mix. In-use 14–31 days. |
| Glargine (Lantus U-100, Toujeo U-300) | 1–2 h / peakless / 22–26 h (U300 >24 h) | U-100 / U-300 | Refrigerate unopened. In-use 28 days / Toujeo 56 days. |
| Detemir (Levemir) | 1–2 h / peakless / 20–24 h | U-100 | Refrigerate unopened. In-use 42 days. |
| Degludec (Tresiba) | 1 h / peakless / 42+ h | U-100 / U-200 | Refrigerate unopened. In-use 56 days. |
| Inhaled (Afrezza) | ~12 min / 30–60 min / 3 h | 4 / 8 / 12 U cartridges | Refrigerate unopened. 10 days at room temp after opening. |
- Injection technique — 4–6 mm pen needles or 29–31G insulin syringes; SubQ at abdomen (fastest absorption), thigh, or upper arm. Rotate sites to prevent lipohypertrophy.
- Do not mix analogs with glargine / degludec — These basal analogs are incompatible with mixing in a syringe (different pH / stabilizers).
- Temperature stability — Freezing denatures insulin; discard if frozen. Temperatures above 30°C accelerate degradation.
- Inspection — Rapid and regular insulin should be clear and colorless. NPH is a white cloudy suspension that should resuspend evenly on rolling; clumps, frosting, or sediment indicate discard.
- Pump-compatible insulins — Rapid analogs are standard for CSII pumps. Regular insulin is compatible but rarely used in modern pump therapy due to its longer duration.
→ Use the Kalios Dosing Calculator for insulin unit-to-mL conversions
Side Effects & Risks
Important
Hypoglycemia is the lethal risk — fast-onset, hard to recognize without diabetic training, and the cause of every reported bodybuilder-insulin death. This is a doctor conversation, full stop, before any insulin reaches a syringe outside the diabetic context.
Insulin has a well-characterized adverse-event profile from 100+ years of use. Hypoglycemia dominates the clinical safety picture.
- Hypoglycemia — potentially fatal — The primary and most dangerous risk. Symptoms progress from sweating, tremor, and confusion to seizures, coma, and death. Severe hypoglycemia may occur within 15–30 minutes of an excess dose. Always carry fast-acting carbohydrate (glucose tablets, juice) on insulin therapy. Non-diabetic use is especially dangerous because the counter-regulatory thresholds and glycemic reserves differ from diabetic patients trained to recognize symptoms.
- Weight gain — Virtually universal with chronic insulin therapy unless tightly managed with diet. Reflects insulin's lipogenic signaling and reversal of pre-treatment glycosuria-associated caloric loss.
- Lipohypertrophy / lipoatrophy — Localized fat accumulation or atrophy at repeated injection sites. Site rotation prevents. Injection into lipohypertrophic tissue produces erratic absorption.
- Hypokalemia — Insulin drives K⁺ intracellularly. Clinically significant in DKA management (potassium must be replaced) and in rapid aggressive insulin loading.
- Edema (insulin edema) — Transient fluid retention after initiating intensive therapy, particularly in patients restored from prolonged hyperglycemia.
- Worsening diabetic retinopathy (early) — Rapid glycemic improvement can transiently worsen retinopathy. Ophthalmologic monitoring during initiation.
- Allergic reactions — Rare with modern human-sequence and analog insulins. Historically more common with bovine / porcine.
- Insulin antibodies — Low-level antibody formation is common; clinically relevant antibody-mediated insulin resistance is rare.
- Mitogenic / cancer concerns (glargine controversy) — 2009 observational studies raised concerns about glargine and breast cancer. Subsequent randomized ORIGIN trial and large meta-analyses have not confirmed a causal signal. Glargine U100 is not considered to carry meaningful excess mitogenic risk.
- Hypoglycemia unawareness — Repeated hypoglycemic episodes blunt counter-regulatory responses and symptom perception — the autonomic warning signs disappear, and the first presentation of the next hypoglycemic event may be neuroglycopenia (confusion, seizure).
- Drug interactions — Beta-blockers mask hypoglycemia symptoms. Alcohol suppresses hepatic gluconeogenesis and potentiates hypoglycemia. Systemic corticosteroids, atypical antipsychotics, and thiazide diuretics antagonize insulin action and may increase insulin requirements.
- Performance / bodybuilding use (critical) — Multiple documented case reports of fatal hypoglycemia, seizure, coma, and hypoglycemic brain injury in non-diabetic insulin users. The most dangerous practice is post-workout "slin" dosing in fed athletes who then train, sleep, or combine with GH — all of which can produce cascade hypoglycemia. This is not a calculated-risk intervention; the risk is catastrophic and under-estimated.
Bloodwork & Monitoring
- Continuous glucose monitoring (CGM) — Dexcom G7, Libre 3, and Medtronic Simplera are the current generation. CGM is now standard of care in T1D and strongly recommended in any patient using basal-bolus insulin. Fingerstick glucose remains the backup and confirmation tool.
- HbA1c — Every 3 months in active management, reflecting 60–90-day average glycemia. ADA general target <7% (individualized).
- Time-in-range (CGM metric) — Percentage of time glucose is 70–180 mg/dL. Increasingly the primary management metric alongside A1c.
- Fasting insulin and C-peptide — For characterizing endogenous production; relevant when diagnosing T1D vs T2D, LADA, MODY.
- Potassium — Monitor during DKA/HHS management and in patients with renal dysfunction on insulin.
- Comprehensive metabolic panel + lipid panel — Baseline and at regular intervals.
- Diabetic screening labs — Annual urine microalbumin, eye exam, foot exam; age-appropriate CV risk management.
- Hypoglycemia log — Record severe events; documented pattern of nocturnal hypoglycemia may prompt basal dose adjustment or degludec / glargine U300 substitution.
- Body composition (performance-context) — For completeness if insulin is used in a clinical context where body composition is tracked. Does not justify or safety-certify non-medical use.
Commonly Stacked With
In diabetes management, insulin is often combined with other glucose-lowering agents. In non-medical performance use, stacking insulin amplifies risk substantially; the combinations below are noted for completeness, not recommended.
Metformin
Standard first-line oral T2D agent. Commonly combined with insulin in T2D to reduce insulin dose requirements and mitigate weight gain. Does not affect hypoglycemia risk directly.
Increasingly preferred add-on to basal insulin in T2D — reduces insulin dose, promotes weight loss, and improves glycemia without adding hypoglycemia risk when added to basal-only insulin. Dose reduction of concurrent sulfonylurea and insulin is required.
SGLT2 inhibitors
Empagliflozin, dapagliflozin, canagliflozin. Glucose-lowering via glycosuria; complementary to insulin. Adds CV and renal protection but raises euglycemic DKA risk in T1D and advanced T2D.
Noted for completeness — the GH + insulin combination is widely cited in bodybuilding literature as the most potent anabolic stack and one of the most dangerous. GH is diabetogenic; insulin offsets GH-induced hyperglycemia but compounds hypoglycemia risk if dose is miscalculated. Multiple published bodybuilder fatalities involve this combination. Not recommended.
Testosterone improves insulin sensitivity; the combination is used in bodybuilding contexts. Does not reduce hypoglycemia risk; does not confer safety to non-medical insulin use.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
Insulin is FDA-approved for type 1 diabetes, type 2 diabetes, diabetic ketoacidosis, hyperosmolar hyperglycemic state, gestational diabetes, and a range of inpatient hyperglycemia indications. Multiple formulations from multiple manufacturers (Eli Lilly, Novo Nordisk, Sanofi, Biocon, and biosimilar producers) are commercially available.
In the United States, regular insulin and NPH (Humulin R, Humulin N, Novolin R, Novolin N) are available without prescription in most states, sold behind the pharmacy counter. All analog insulins (lispro, aspart, glulisine, glargine, detemir, degludec) require a prescription. Insulin is not a controlled substance but is a high-potency pharmaceutical with documented lethal potential.
Biosimilar insulin glargine (Semglee, Basaglar, Rezvoglar) and biosimilar lispro (Admelog) are FDA-approved and have substantially expanded access since 2017. Interchangeable biosimilars can be substituted at the pharmacy level without physician re-authorization in most states.
Insulin is prohibited by the World Anti-Doping Agency under Section S4 (Hormone and Metabolic Modulators) — prohibited both in- and out-of-competition, with therapeutic use exemption available for documented insulin-dependent diabetes. Most major sports federations follow the WADA Code.
Insulin is not a Category 2 bulk drug substance and is not part of the HHS Secretary Robert F. Kennedy Jr. February 2026 peptide reclassification announcement — it is an approved branded / biosimilar drug, not a compounding-pathway peptide.
Cost & Access
Insulin is available by prescription through retail pharmacies nationwide (and without prescription for Humulin R / N, Novolin R / N behind the counter in most states). Commercial insurance coverage is broad but plan tiering varies substantially across branded analogs, authorized generics, and biosimilars.
Federal and state insulin affordability programs have substantially reshaped access since 2022. The Inflation Reduction Act capped Medicare Part D insulin out-of-pocket at a low monthly level starting 2023. Eli Lilly, Novo Nordisk, and Sanofi implemented voluntary patient assistance caps for commercial and uninsured patients in 2023. Authorized generics (Lispro, Aspart, Glargine Sanofi authorized generic) are available as lower-tier alternatives at retail pharmacies.
Biosimilars (Semglee, Basaglar, Rezvoglar for glargine; Admelog for lispro; Rezvoglar interchangeable status 2022) further expand access. Mail-order pharmacy and 340B-affiliated clinics often provide additional pathways for low-income patients. Patient-assistance foundation programs (Lilly Insulin Value Program, Novo Nordisk Patient Assistance Program, Sanofi Patient Connection) remain active as of April 2026.
Kalios does not sell compounds. Insulin for diabetes management should be obtained through a licensed physician and dispensed through a licensed pharmacy — the safety margin for dosing errors requires pharmacy-grade formulation and patient education that is outside the scope of any research-chemical channel.
Pricing, formulary status, and affordability programs are updated frequently; check current manufacturer and insurer resources. Kalios does not sell compounds.
Related Compounds
People researching insulin often also look at these:
Long-arginine-3 insulin-like growth factor 1. Extended half-life IGF-1 analogue. Anabolic and pro-hypertrophic.
Synthetic amylin analogue (Symlin). Post-prandial glucose and satiety modulator.
Dual GIP/GLP-1 receptor agonist (Mounjaro / Zepbound). Superior weight-loss and glycemic efficacy vs semaglutide.
Des(1-3) IGF-1 variant with higher tissue potency through reduced IGFBP binding.
Key References
- Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med. 1922;7(5):251-266. (Foundational discovery of insulin.)
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. PMID: 8366922.
- Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287(19):2563-2569. PMID: 12351001.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. PMID: 9742976.
- Gerstein HC, Bosch J, Dagenais GR, et al; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. PMID: 22686416.
- Marso SP, McGuire DK, Zinman B, et al; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. PMID: 28605603.
- Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997;46(2):265-270. PMID: 9000704.
- Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24(4):631-636. PMID: 11315821.
- Biolo G, Tipton KD, Klein S, Wolfe RR. An abundant supply of amino acids enhances the metabolic effect of exercise on muscle protein. Am J Physiol. 1997;273(1 Pt 1):E122-E129. PMID: 9252488.
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. PMID: 18784090. (UKPDS legacy follow-up.)
- Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes (ACCORD). N Engl J Med. 2008;358(24):2545-2559. PMID: 18539917.
- Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086. PMID: 14578243.
- Elkin SL, Brady S, Williams IP. Bodybuilders find it easy to obtain insulin to help them in training. BMJ. 1997;314(7090):1280. PMID: 9135470.
- Evans PJ, Lynch RM. Insulin as a drug of abuse in body building. Br J Sports Med. 2003;37(4):356-357. PMID: 12893725.
- Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009;53(5 Suppl):S14-S20. PMID: 19179212.
- Kahn CR. The molecular mechanism of insulin action and the regulation of glucose and lipid metabolism. Annu Rev Med. 1985;36:429-451. PMID: 2986528.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1-S352.
- Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm — 2020 executive summary. Endocr Pract. 2020;26(1):107-139. PMID: 32022600.
- World Anti-Doping Agency. 2026 Prohibited List — Section S4: Hormone and Metabolic Modulators. wada-ama.org.
- U.S. Food and Drug Administration. Humulin, Humalog, Novolog, Lantus, Toujeo, Levemir, Tresiba prescribing information. FDA.gov.
Last updated: April 2026 | Profile authored by Kalios Peptides research team